Using genetic testing to improve psychiatric medication for kids
Pharmacogenetic Supported Prescribing in Kids
NA · University of Calgary · NCT04797364
This study is testing whether genetic testing can help kids and teens find the right psychiatric medications faster and with fewer side effects.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 6000 (estimated) |
| Ages | 6 Years to 24 Years |
| Sex | All |
| Sponsor | University of Calgary (other) |
| Locations | 1 site (Calgary, Alberta) |
| Trial ID | NCT04797364 on ClinicalTrials.gov |
What this trial studies
This project implements pharmacogenetic testing for children and adolescents aged 6-24 who are starting or changing psychiatric medications. It aims to reduce the trial-and-error approach currently used in prescribing mental health medications by identifying genetic factors that influence drug efficacy and adverse reactions. The study will evaluate the effectiveness of this testing service in improving treatment outcomes and will collect data on performance and economic indicators. The ultimate goal is to enhance the well-being of children with mental health conditions through more personalized medication strategies.
Who should consider this trial
Good fit: Ideal candidates are children and adolescents aged 6-24 with moderate to severe mental health conditions who are starting or changing psychiatric medications.
Not a fit: Patients who are medically unstable, unable to provide informed consent, or unwilling to participate in genetic testing may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective psychiatric treatments with fewer adverse effects for children and adolescents.
How similar studies have performed: Other studies have shown promise in using pharmacogenetic testing to improve medication outcomes, making this approach a potentially valuable advancement in pediatric mental health care.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Medical records available * The initiation, change, dose adjustment, or augmentation of psychiatric medication(s) is indicated * Treating psychiatrist, family physician, or pediatrician licensed in Alberta, British Columbia, Saskatchewan, or Manitoba requests pharmacogenetic testing Exclusion Criteria: * Medically unstable or lacking capacity to provided informed consent * Unwillingness of child to provide saliva sample for genetic analysis * History of liver or bone marrow (hematopoietic cell) transplant
Where this trial is running
Calgary, Alberta
- University of Calgary — Calgary, Alberta, Canada (RECRUITING)
Study contacts
- Principal investigator: Chad Bousman, PhD — University of Calgary
- Study coordinator: Laina McAusland, MSc
- Email: psychpgxlab@ucalgary.ca
- Phone: 403-210-6353
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Mental Health Impairment, Child, Adolescent, Mental Health, Psychiatry, Pharmacogenetics, Depression, Anxiety